Pediatrics

This schedule arrives at a time of unprecedented friction between leading medical societies and federal health agencies.

Alongside malnutrition instances and measles cases, researchers review pneumonia disease burden and immune vulnerability across high-risk pediatric groups.

The executive order calls to realign core childhood vaccine recommendations with scientific evidence and best practices of peer, developed nations.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

New FDA label lets linaclotide treat functional constipation in children 2 to 5, with dosing tips, mixing options, and key safety warnings.

Utah protocol streamlines large-volume immunoglobulin for measles-exposed infants as outbreaks surge.

The drug’s indication for uncontrolled chronic spontaneous urticaria is the first biologic medicine of its kind, specifically explored amongst children 2 to 11 years old.

FDA expands Tzield use to age 1 year to delay stage 3 type 1 diabetes, enabling earlier immune intervention.

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

FDA expands lomitapide use to children 2 years and older, highlighting major low-density lipoprotein reductions.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

Exploring the perspectives of health care professionals, researchers test the feasibility of the Asthma Care from Home project.

Inhaled Technosphere insulin revolutionizes diabetes management for children and pregnant women, addressing treatment adherence and psychological barriers effectively.

The American Academy of Pediatrics responds to recent HHS vaccine guideline changes with its own schedule for childhood and adolescent patients.

Amid evolving recommendations for products like acetaminophen as well as influenza vaccines, researchers revisit the role of pharmacists in addressing adolescents’ cold and flu symptoms.

Medical organizations challenge the government's revised childhood vaccine schedule, urging Congress for immediate oversight and action to protect public health.

Fremanezumab significantly reduces migraine days in children and adolescents, offering a vital preventive option for managing episodic migraines.

This marks the disease’s very first treatment option for pediatric patients looking to manage Menkes and its symptoms.

Mavacamten shows promise in treating adolescent obstructive hypertrophic cardiomyopathy, significantly improving heart function and safety in a pivotal trial.

US adults were surveyed about their understanding of shared clinical decision-making following the HHS overhaul of childhood vaccines.

Although several vaccines are still being recommended, a variety of those protecting against respiratory viruses and other diseases have been narrowed on child vaccine schedules.

Amid a lack of research on their specific perspectives, women with epilepsy share their experiences with pregnancy and reproductive health.

Pediatric obesity rates surge, prompting a debate on GLP-1 agonists versus traditional treatments, highlighting efficacy, risks, and long-term implications.

This announcement is another move stemming from the federal government's skeptic views on vaccine technology and its efficacy among US patients.

Researchers want to bolster evidence regarding the known link between maternal mental health and childhood nutritional status.